MARKET

XOMA

XOMA

Xoma Corp Del
NASDAQ
17.91
-0.49
-2.66%
After Hours: 17.91 0 0.00% 16:49 09/30 EDT
OPEN
18.14
PREV CLOSE
18.40
HIGH
18.47
LOW
17.80
VOLUME
12.58K
TURNOVER
0
52 WEEK HIGH
32.09
52 WEEK LOW
15.68
MARKET CAP
205.08M
P/E (TTM)
55.21
1D
5D
1M
3M
1Y
5Y
XOMA Corp On Sept. 28 Made $3M Milestone Payment To Affitech Research As Pursuant To Commercial Payment Purchase Agreement
- Reuters
Benzinga · 2d ago
XOMA Reports Quarterly Preferred Stock Dividends Payable Oct. 17 to Holders of Record Oct. 3
XOMA Reports Quarterly Preferred Stock Dividends Payable Oct. 17 to Holders of Record Oct. 3
MT Newswires · 09/21 08:04
Starbucks And 3 Other Stock Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades.
Benzinga · 09/19 14:57
Time To Worry? Analysts Are Downgrading Their XOMA Corporation (NASDAQ:XOMA) Outlook
Market forces rained on the parade of XOMA Corporation ( NASDAQ:XOMA ) shareholders today, when the analysts downgraded...
Simply Wall St. · 08/11 10:22
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 14:45
XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
XOMA press release (<span class="ticker-hover-...
Seekingalpha · 08/04 12:29
BRIEF-Xoma Reports Q2 Revenue Of $1.0 Million
BRIEF-Xoma Reports Q2 Revenue Of $1.0 Million
Reuters · 08/04 11:55
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 196% gain
While XOMA Corporation ( NASDAQ:XOMA ) shareholders are probably generally happy, the stock hasn't had particularly...
Simply Wall St. · 06/30 11:33
More
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. It also acquires the economics associated with pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company has a portfolio of more than 70 assets. Its royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087), a clinical-stage anti-IL-1b product candidate; scalimab (CFZ533); mezagitamab (TAK-079); RZ358; AZD2936, a TIGIT/PD-1 bispecific antibody; MK-4830, and others. The Company's geographical segments include Europe, United States and Asia Pacific.

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.